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Induction of protein catabolism in myotubes by
15(S)-hydroxyeicosatetraenoic acid through increased
expression of the ubiquitin–proteasome pathway
AS Whitehouse1, J Khal1 and MJ Tisdale*,1
1Pharmaceutical Sciences Research Institute, Aston University, Birmingham B4 7ET, UK
The potential role of 15(S)-hydroxyeicosatetraenoic acid (15(S)-HETE) as an intracellular signal for increased protein catabolism and
induction of the expression of key components of the ubiquitin–proteasome proteolytic pathway induced by a tumour cachectic
factor, proteolysis-inducing factor has been studied in murine C2C12 myotubes. 15(S)-HETE induced protein degradation in these
cells with a maximal effect at concentrations between 78 and 312 nM. The effect was attenuated by the polyunsaturated fatty acid,
eicosapentaenoic acid (EPA). There was an increase in ‘chymotrypsin-like’ enzyme activity, the predominant proteolytic activity of the
proteasome, in the same concentration range as that inducing total protein degradation, and this effect was also attenuated by EPA.
15(S)-hydroxyeicosatetraenoic acid also increased maximal expression of mRNA for proteasome subunits C2 and C5, as well as the
ubiquitin-conjugating enzyme, E214k, after 4 h incubation, as determined by quantitative competitive RT–PCR. The concentrations of
15-HETE affecting gene expression were the same as those inducing protein degradation. Western blotting of cellular supernatants of
myotubes treated with 15(S)-HETE for 24 h showed increased expression of p42, an ATPase subunit of the regulatory complex at
similar concentrations, as well as a decrease in expression of myosin in the same concentration range. 15(S)-hydroxyeicosatetraenoic
acid activated binding of nuclear factor-kB (NF-kB) in the myotube nucleus and stimulated degradation of I-kBa. The effect on the
NF-kB/I-kBa system was attenuated by EPA. In addition, the NF-kB inhibitor peptide SN50 attenuated the increased chymotrypsin-
like enzyme activity in the presence of 15(S)-HETE. These results suggest that 15(S)-HETE induces degradation of myofibrillar
proteins in differentiated myotubes through an induction of an increased expression of the regulatory components of the ubiquitin–
proteasome proteolytic pathway possibly through the intervention of the nuclear transcription factor NF-kB, and that this process is
inhibited by EPA.
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Proteolysis through the ubiquitin–proteasome pathway has an
important role in the regulation of the cell cycle and division,
differentiation and development, as well as a variety of other basic
cellular processes (Ciechanover et al, 2000). In addition, this
pathway plays an important role in the wasting of skeletal muscle
seen in a range of catabolic processes, including starvation, sepsis,
metabolic acidosis, weightlessness, severe trauma, denervation
atrophy and cancer cachexia (Lecker et al, 1999). In this process,
proteins are degraded into peptides within the 20S proteasome, a
cylindrical structure of four stacked rings, each composed of seven
subunits surrounding a central cavity. The inner b rings contain
proteolytic enzymes, while the two outer a rings surround a small
cavity through which protein substrates must enter. Cellular
proteins are marked for degradation by attachment of a
polyubiquitin chain. While the ubiquitin-conjugating enzyme
(E214k) was suggested to be the rate-limiting step in the pathway
in starvation (Wing and Banville, 1994), it has recently been shown
that E214k knockout is not associated with decreased protein
catabolism (Adegoke et al, 2002). Instead, ubiquitin-protein ligases
(E3) may play a more important role in muscle atrophy and E3
knockout is clearly associated with increased protein catabolism
(Bodine et al, 2001; Gomes et al, 2001).
Despite the importance of the ubiquitin–proteasome pathway,
there is little information on intracellular signals leading to an
increased gene transcription of the rate-limiting enzymes. It has
been suggested that glucocorticoids and a low insulin level in
tandem activate the ubiquitin–proteasome proteolytic system
(Mitch et al, 1999). Glucocorticoids increase protein catabolism by
opposing the suppression of the transcription of the proteasome
C3 a-subunit by nuclear factor-kB (NF-kB), by antagonising the
interaction of NF-kB with an NF-kB response element in the C3
subunit promoter region (Du et al, 2000). Also physiological levels
of glucocorticoids are necessary, but not sufficient for the catabolic
response in rats with metabolic acidosis (Price et al, 1994),
starvation (Wing and Goldberg, 1993) and sepsis (Tiao et al, 1996).
However, chronic excessive glucocorticoid production, as occurs
in Cushing’s syndrome is not associated with an increased mRNA
for ubiquitin, the ubiquitin-conjugating enzyme, E214k, or protea-
some subunits (Ralliere et al, 1997), suggesting that other factors
may be involved.
We have isolated a sulphated glycoprotein of Mr 24 000
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(Todorov et al, 1996), which induces proteolysis directly in
isolated skeletal muscle (Lorite et al, 1997) and in C2C12 murine
myoblasts in the absence of glucocorticoids (Smith et al, 1999).
This factor, named proteolysis-inducing factor (PIF), induces
release of arachidonic acid from muscle cells with an increased
production of prostaglandin (PG) E2 and F2a together with
metabolism through the lipoxygenase pathways to 5-, 12-, and
15-hydroxyeicosatetraenoic acids (HETEs) (Smith et al, 1999).
Release of arachidonic acid and its subsequent metabolism was
shown to be directly related to the induction of protein catabolism,
since it was completely attenuated in the presence of eicosapen-
taenoic acid (EPA), which also completely inhibited protein
degradation induced by PIF. Of the metabolites of arachidonate
only 15(S)-HETE produced a significant increase in protein
degradation alone, suggesting that it acts as an intracellular signal
for the action of PIF. Since PIF has been shown to upregulate the
ubiquitin–proteasome pathway (Lorite et al, 1998), this suggests
that 15(S)-HETE should also induce the key regulatory compo-
nents of this pathway.
This study utilizes an in vitro model of skeletal muscle (C2C12
myotubes) to investigate the effect of 15(S)-HETE on protein
degradation and protein and mRNA levels of the key enzymes of
the ubiquitin–proteasome pathway, as well as the involvement of
potential transcription factors.
MATERIALS AND METHODS
Materials
L-[2,6-3H]Phenylalanine (sp. act. 2.00 TBqmmol1) was purchased
from Amersham International (Bucks, UK). Foetal calf serum
(FCS), horse serum (HS) and Dulbecco’s modified Eagle’s medium
(DMEM) were purchased from Life Technologies (Paisley, Scot-
land). Mouse anti-p42 antibody was a gift from Dr Jane Arnold,
UK. Mouse monoclonal antibody to myosin heavy chain was
purchased from Novocastra (Newcastle-upon-Tyne, UK). Rabbit
polyclonal antisera to residues 1–317 of human I-kBa was
purchased from Santa Cruz Biotechnology Inc., CA, USA.
Peroxidase-conjugated rabbit antimouse antibody was purchased
from Dako Ltd, Cambridge, UK and peroxidase-conjugated goat
anti-rabbit antibody from Sigma Chemical Co., Dorset, UK. 15(S)-
HETE was purchased from Biomol Research Laboratories Inc., PA,
USA. Oligonucleotides for EMSA, T4 polynucleotide kinase 10
buffer and gel shift binding buffer were from Santa Cruz
Biotechnology Inc., CA, USA. SN50 was purchased from Calbio-
chem, Nottingham, UK. Wizardt mini or maxi preps, used to
prepare plasmid DNA from overnight cultures of bacterial clones,
were obtained from Promega, UK (Southampton), as were the T7
RNA polymerase kit, RNAsin inhibitor, reverse transcriptase,
reverse transcription buffer and PCR grade magnesium chloride.
Taq polymerase and Hybond C were from Amersham Biosciences,
UK Ltd (Bucks, UK), TRI reagent for RNA isolation was purchased
from Sigma-Aldrich, Co-Ltd (Dorset, UK), while the oligonucleo-
tide primers were from MWG Biotech (Ebersberg, Germany). RNA
storage buffer was purchased from Ambion Ltd (Cambridgeshire,
UK) and PCR buffer from Roche, Switzerland.
Cell culture
The C2C12 myoblast cell line was grown in DMEM supplemented
with 10% FCS plus 1% penicillin and streptomycin under an
atmosphere of 10% CO2 in air at 371C. Myotubes were formed by
allowing confluent cultures of myoblasts to fuse in DMEM
containing 2% HS over a 7-day period, with changes of medium
every 2 days.
Measurement of total protein degradation
This was measured essentially as previously described for murine
myoblasts (Lorite et al, 2001). Myotubes were formed in six-well
multidishes containing 2ml DMEM and 2% HS. Cells were labelled
for 24 h with L-[2,6-3H] phenylalanine (0.67mCimmole1), and
washed three times in PBS. They were then incubated for 2 h in
DMEM without phenol red until no more radioactivity appeared in
the supernatant, and then for a further 24 h period with various
concentrations of 15(S)-HETE in fresh DMEM without phenol red
to reduce quenching of counts, and in the presence of 2mM cold
phenylalanine to prevent reincorporation of radioactivity. The
amount of radioactivity released into the medium was determined
using a 2000CA Tri-Carb liquid scintillation analyzer and is
expressed as a percentage of control cultures determined from
myotubes incubated with the [3H]phenylalanine for 24 h, but not
treated.
Measurement of proteasome activity
The functional activity of the b-subunits of the proteasome was
determined as the ‘chymotrypsin-like’ enzyme activity determined
fluorimetrically according to the method of Orino et al, (1991).
Cells were sonicated in 20mM Tris-HCl, pH 7.5, 2mM ATP, 5mM
MgCl2 and 1mM dithiothreitol (DTT) at 41C and enzyme activity
was determined on the supernatant fraction, formed by centrifu-
gation for 10min at 18 000 g, using the fluorogenic substrate
succinyl-LLVY-AMC (0.1mM) in the presence or absence of 10mM
lactacystin, a specific proteasome inhibitor (Fenting and Schreiber
1998). Only lactacystin suppressible activity was considered to be
proteasome specific. The reaction was terminated by the addition
of 80mM sodium acetate, pH 4.3, and the fluorescence determined
with an excitation wavelength of 360 nm and an emission
wavelength of 460 nm. The activity was adjusted for the protein
concentration of the sample, determined using the Bradford assay
(Sigma Chemical Co., Dorset, UK). Both substrate and enzyme
concentrations were optimal and the results were similar to those
obtained using purified proteasomes (Lorite et al, 2001).
Western blot analysis
Myotubes were treated with various concentrations of 15(S)-HETE,
with or without 2 h preincubation with 50mM EPA. The medium
was removed and the cells were washed with PBS, followed by
scraping from the plastic surface and sonication in 500–2000ml of
the buffer used to measure proteasome activity. After centrifuga-
tion (18 000 g for 5min), the supernatant was assayed for protein
concentration using a colourimetric protein assay (Biorad, UK).
Samples of cytosolic protein (2.5mg) were resolved on 12% sodium
dodecylsulphate, polyacrylamide gels (SDS/PAGE) and transferred
to 0.45mm nitrocellulose membranes (Hybond A, Amersham, UK),
which had been blocked with 5% Marvel in Tris-buffered saline,
pH 7.5, at 41C overnight. The primary antibodies were used at a
1 : 1500 dilution, except for myosin heavy chain used at 1 : 250
dilution and I-kBa at 1 : 400. The secondary antibodies were used
at a 1 : 2000 dilution. Incubation was for 1 h at room temperature
and development was by enhanced chemiluminescence (ECL)
(Amersham, UK). Blots were scanned by a densitometer to
quantitate differences, and a parallel gel was silver stained to
ensure equal loading.
Quantitative competitive RT–PCR
Total RNA was extracted from muscle using TRI-reagent and the
RNA concentration was determined from the absorbance at
260 nm. To quantitate the mRNA of interest, increasing amounts
of competitor RNA, which differed from the mRNA of interest by
containing a short deletion, were added to 250 ng of total RNA and
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coamplified using RT–PCR. The amount of specific mRNA was
calculated from the amount of competitor, when equal amounts of
PCR product were obtained from the competitor and target RNA,
as previously described (Wang et al, 1989; Taylor et al, 1998).
The C2 competitor was obtained from the mouse gene using the
primer pairs: 50CGCACGGAGTGCTGGTTGCAC30 and 50GTACGA
GCTGATTGAGAACGG–CATAACCAGCAATGAGCAGCC30 at po-
sitions 176–187 and 531–552 bp to 435–455 bp, respectively,
which produced a DNA fragment containing a 76-bp deletion. The
C5 competitor was obtained from the mouse gene using the primer
pairs: 50TCAACGGAGGTACTGTATTGG30 and 50GCATGGCACTT
GCTGAGCC–GCATGGCACTTGCTGAGCC30 at positions 101–121
and 496 to 514 bp to 358–378 bp, respectively, producing a DNA
fragment containing a 117-bp deletion. The E214k competitor was
obtained from the rat gene using the primer pairs: 50CTCATGC
GGGATTTCAAGCG30 and 50CTCTTCTCATACTCCCGTTTGCAT–
CGGTTCTGCAGGATGTC30 at positions 68–87 and 443–468 bp to
312–321 bp, respectively, producing a DNA fragment containing a
111-bp deletion. The competitor DNAs were blunt ended and then
ligated into a pET30a vector, which had been blunt-end cut with
Smal restriction enzyme. The ligated vector was used to transform
DH5a competent cells. Plasmid DNA was prepared from PCR-
positive clones using Wizard-mini-prep. Competitor RNA was
produced using T7 RNA polymerase kit, and quantitated using the
optical density at 260 nm. Six serial two-fold dilutions were
prepared containing known concentrations of competitor. The
particular dilutions used were selected to span the selected
concentration of C2, C5 and E214k in the sample.
To synthesise the cDNA template, a mixture consisting of 250 ng
target RNA, the particular dilution of the competitor RNA and
0.5mg of random hexamer was incubated at 701C for 5min in a
thermal cycler (Genetic Research, Instrumentation Ltd, Essex, UK)
and then chilled on ice before the addition of 2.5 ml 5 reverse
transcription buffer, 3 ml of 10mM each at dATP, dGTP, dCTP,
dTTP, 5U of RNAsin inhibitor and 1U reverse transcriptase in a
total volume of 12.5ml. Incubation was at 371C for 1 h. For the
amplification of the cDNA by PCR, 50 ml of PCR mix was added to
each tube. The PCR mixture contained 1 PCR buffer (without
magnesium) together with 3mM MgC12 (E2), 3.5mM MgCl2 (C5)
and 2.5mM MgCl2 (C2) together with 1U Taq polymerase. For the
E2 gene, 10 pmol of each of the primers 50CTCATGCGGGA
TTTCAAGCG30 and 50CTCTTCTCATACTCCCGTTTG30 were used,
while for the C5 gene 10 pmol of each of the primers 50TCAAC
GGAGGTACTGTATTGG30 and 50GCATGGCACTTGCTGAGCC 30
were used. For the C2 gene, 20 pmol of each of the primers 50CGCA
CGCAGTGCTGGTTGCAC30 and 50GTACGAGCTGATTGAGAAC
GG30 were used. The temperature-cycling profile for amplification
was as follows: 951C for 2min for one cycle followed by 951C for
30 s, 581C annealing for 1min and 721C extension for 1min for 30
cycles. Control reactions containing all components except reverse
transcriptase and another without template were carried out
alongside each experiment to show that the RNA (both target and
competitor) had no DNA contamination, while the second control
showed that there was no contamination in the PCR mixture.
Coamplification of E2 target and competitor produced DNA
fragments of 395 and 284 bp, respectively; C2 target
and competitor produced 385 and 309 bp fragments and C5
target and competitor produced 414 and 297 bp fragments,
respectively.
For analysis of results, 15 ml of PCR products were separated on
a 2% (w v1) agarose gel containing ethidium bromide. The gel
images were visualised on a UV transilluminator and photo-
graphed. The intensity of the bands were quantitated using a
Phoretix photo-imager programme. The volumes of the competitor
and target bands were plotted against the known serial dilutions of
the competitor used in the experiment. The amount of the sample
RNA corresponds to the amount of competitor when the ratio of
competitor to target is 1.0. A representative gel showing
competitor and target RNA, as well as a dose–response curve is
shown in Figure 1.
Preparation of nuclear proteins
Cell monolayers were rinsed, scraped and pelleted in 10mM
HEPES, pH 7.5, 10mM KCl, 2mM MgCl2, 1mM DTT, 0.1mM
EDTA, 0.4mM PMSF, 0.2mM NaF, 0.2mM sodium orthovanadate
and 0.3mgml1 leupeptin. The pellets were resuspended in 300 ml
of the same wash buffer and incubated on ice for 15min. Lysis was
achieved by the addition of 30 ml of 1% Triton X-100, followed by
vortexing, and nuclei were pelleted by a 30 s centrifugation at
14 000 r.p.m., and the supernatant was thoroughly removed. The
nuclear pellet was resuspended in 50 ml ice-cold lysis buffer (50mM
HEPES, pH 7.8, 50mM KCl, 0.3 M NaCl, 0.1mM EDTA and 1mM
DTT) and the suspension was kept on ice for 20min with a 30 s
vortex every 3–5min. Centrifugation at 14 000 r.p.m. for 5min
yielded the supernatant containing the protein extract.
Electrophoretic mobility shift assay
The transcription factor consensus oligonucleotides for the NF-
KB-responsive element (50AGT TGA GGG GAC TTT CCC AGG
C30) was purchased from Promega (Southampton, UK). The
probes were labelled with [g-32P]ATP by using T4 polynucleotide
kinase (Promega) for 10min at 371C. For the binding reaction,
nuclear extract (10mg protein) was incubated in a 10ml volume
with 2 ml EMSA binding buffer (20% glycerol; 5mM MgCl2; 250mM
NaCl; 2.5mM EDTA; 2.5mM DTT; 50mM Tris-HCl, pH 7.5 and
0.25mgml1 poly (dI-dC)-poly (dI-dC) and 1 ml g-32P-labelled
probe for 20min at room temperature following a 10min
preincubation in the absence of the labelled probe. The specificity
of the binding reaction was determined by coincubating duplicate
samples with unlabelled probes. A negative control reaction was
also included which contained everything except sample. Protein–
nucleic acid complexes were resolved using an 8% nondenaturing
polyacrylamide gel and a native 5% polyacrylamide stacking gel in
25mM Tris, pH glycine for 30min at 150mV. Gels were dried
M RT−ve  PCR−ve  1        2        3        4        5
500 bp
300 bp
Target
Competitor
120 000.00
80 000.00
40 000.00
0.00
Ba
nd
 v
ol
um
e
0.3 0.15 0.075 0.0375 0.01875
C5 competitor (ng)
A
B
Figure 1 (A) Representative gel illustrating quantitative competitive
RT–PCR for C5 mRNA in control cultures at 4 h incubation. Lanes: M;
100-bp DNA ladder: RT-ve; without reverse transcriptase, PCR-ve: without
template. Lanes 1–5 each contain 0.25 mg target RNA and a specific
amount of the C5 competitor RNA ranging from 0.01875 to 0.3 ng in two-
fold dilutions. (B) Dose–response curve from the gel shown in (A). ’,
target volume; m, competitor volume. The amount of unknown
determined from where the two lines intersect¼ 0.0445 ng mRNA.
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between Whatman 3M filter paper (Whatman Inc., Clifton, NJ,
USA), dried under vacuum at 801C for 1 h and exposed to
‘Hyperfilm MP’ (Amersham Pharmacia Biotech) for 48 h at 701C.
Statistical analysis
Results are presented as mean7s.e.m. Differences were deter-
mined by one-way ANOVA, followed by Tukey’s test.
RESULTS
The effect of 15(S)-HETE on total protein degradation in C2C12
myotubes, as measured by [3H]phenylalanine release, is shown in
Figure 2A. The concentrations of 15(S)-HETE chosen were based
on those produced by PIF in murine myoblasts (Smith et al, 1999).
In this study PIF increased 15-HETE production from 25 to
70 nmol per 5 106 cells per 2 h, that is, an increase of 9 nmol per
106 cells. If all the 15-HETE entered the cells in the current
experiments, this would give a value between 1.4 and 6 nmol per
106 cells. As previously reported in C2C12 myoblasts, 15(S)-HETE
produced a significant increase in [3H]phenylalanine release with a
bell-shaped dose–response curve, although the concentrations
producing maximal protein catabolism (78–156 nM) were higher
than required in myoblasts (Smith et al, 1999). A similar dose–
response curve is observed with PIF (Smith et al, 1999), and with
protein breakdown in muscle of tumour-bearing animals (De-
Blaauw et al, 1997), and may result from downregulation of
receptors, or receptor desensitisation as occurs in the stimulation
of lipolysis by isoprenaline. The effect was attenuated down to
control values in the presence of 50 mM EPA at all concentrations of
15(S)-HETE (Figure 2A), as well as the highly specific and
irreversible proteasome inhibitor, lactacystin (data not shown),
suggesting that the action of 15(S)-HETE may be mediated through
the ubiquitin–proteasome proteolytic pathway. This concentration
of EPA has been previously shown to attenuate PIF-induced
protein catabolism in murine myoblasts (Smith et al, 1999). Lower
concentrations of EPA had no effect. The plasma concentration of
EPA in humans consuming large doses would be in the range 100–
200mM. To determine if proteasome proteolytic activity was also
increased by 15(S)-HETE, the ‘chymotrypsin-like’ enzyme activity,
the predominant proteolytic activity of the proteasome, was
determined using the fluorogenic substrate Suc LLVY-MCA. The
results presented in Figure 2B show that 15(S)-HETE induced
upregulation of the ‘chymotrypsin-like’ activity of the proteasome,
with maximal effect in the concentration range 78–312 nM, as for
total protein catabolism (Figure 2A). As with protein catabolism,
proteasome proteolytic activity was attenuated in cells pretreated
with 50 mM EPA.
To determine whether the increased proteasome proteolytic
activity arose from an increased gene expression mRNA levels of
proteasome subunits C2(a) and C5(b), as well as the ubiquitin-
conjugating enzyme, E214k, were determined in C2C12 myotubes
exposed to various concentrations of 15(S)-HETE for various times
to determine the earliest time of gene induction and how long this
persisted, using quantitative competitive RT–PCR (Figure 3).
Expression of the mRNA for the 20S proteasome subunits C2
(Figure 3A) and C5 (Figure 3B) was significantly increased with
15(S)-HETE concentrations in the range 78–312 nM after 4 h, as for
protein catabolism with a similar bell-shaped dose–response
curve. The level of expression of mRNA for C5 was approximately
2000-fold greater than for C2. Expression of mRNA for E214k was
also significantly increased 4 h after treatment with 15(S)-HETE
(Figure 3C), although the concentration range was somewhat
broader than for proteasome subunits (78–780 nM). The extent of
induction of C2, C5 and E214k by 15(S)-HETE at 2 h (Figure 5) was
less than that observed at 4 h. The increased expression of
proteasome subunits in the presence of 15(S)-HETE was attenu-
ated by prior treatment with EPA (Figure 4). There was also
evidence for an increased expression of mRNA for both C2
(Figure 6A) and C5 (Figure 6B) proteasome subunits after 24 h. As
with studies on PIF (Gomes-Marcondes et al, 2002), higher
concentrations of 15(S)-HETE produced increases in proteasome
mRNA expression at 24 h than at 4 h (Figure 3).
To determine whether increased mRNA expression for protea-
some subunits C2 and C5 was reflected in higher protein levels of
other subunits, cellular supernatants of C2C12 myotubes treated
with 15(S)-HETE for 24 h were immunoblotted for p42, an ATPase
subunit of the 19S regulator that promotes ATP-dependent
association of the 20S proteasome with the 19S regulator to form
the 26S proteasome (Tanahashi et al, 1999) (Figure 7A). Maximal
expression was seen at concentrations of 15(S)-HETE between 156
and 312 nM, which is in the range where an increased proteasome
mRNA expression was seen (Figure 3). Activation of proteasome
expression was associated with a decrease in myosin expression in
the same concentration range (78–312 nM) (Figure 7B). These
results suggest that 15(S)-HETE leads to an increased expression of
the ubiquitin–proteasome pathway, with an increase in overall
protein degradation and depletion of myofibrillar proteins.
The NF-kB transcriptional pathway was investigated as a
possible mediator of the increased expression of the ubiquitin–
proteasome pathway, since NF-kB has been shown to be an
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Figure 2 (A) Effect of 15(S)-HETE on total protein degradation in
C2C12 myotubes after incubation for 24 h in cells either olive oil-treated
(closed boxes) or pretreated for 2 h with 50 mM EPA (hatched boxes).
Results are shown as mean7s.e.m. of one experiment where n¼ 3, and
the experiment was repeated three times on different days with similar
results. Differences from controls in the absence of 15(S)-HETE are
indicated as (a) Po0.05, (b) Po0.01 or (c) Po0.001, while differences in
the presence of EPA from those in the absence are indicated as (d)
Po0.05, (e) Po0.01 and (f) Po0.001. (B) The effect of 15(S)-HETE on
the proteasome ‘chymotrypsin-like’ enzyme activity in C2C12 myotubes
either alone (E) or after pretreatment with 50mM EPA (&). Results are
shown as mean7s.e.m. where n¼ 3 and the experiment was repeated
three times with similar results. Differences from controls in the absence of
15(S)-HETE are indicated as (a) Po0.05 and (b) Po0.01, while differences
in the presence of EPA are indicated as (c) Po0.01 and (d) Po0.001.
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essential mediator of TNF-a-induced protein catabolism in
differentiated muscle cells (Li and Reid, 2000). As shown in
Figure 8A, 15(S)-HETE induced elevated levels of NF-kB DNA
binding activity in the myotube nucleus, after a 30min incubation,
with a maximal effect between 156 and 234 nM. Increased nuclear
accumulation of NF-kB was not seen after pretreatment with EPA.
Depletion of I-kBa from the cytosol was determined by
immunoblotting of cytoplasmic extracts from the same cells in
which NF-kB translocation was measured. Rapid breakdown of I-
kBa was evident 30min after treatment with 156 nM 15(S)-HETE
(Figure 8B), and this was not seen in cultures pretreated with 50 mM
EPA, suggesting a mechanism by which EPA could downregulate
the increased proteasome expression seen in the presence of 15(S)-
HETE. The NF-kB inhibitor peptide, SN50 (Lin et al, 1995)
attenuated the increased chymotrypsin-like enzyme activity in the
presence of 15(S)-HETE (Figure 8C), suggesting the NF-kB may be
involved in transcriptional activation induced by 15(S)-HETE.
DISCUSSION
There are three main pathways for the intracellular catabolism of
proteins in skeletal muscle; lysosomal proteases, a nonlysosomal
calcium-activated process involving the cysteine proteases calpains
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Figure 3 Effect of treatment of C2C12 myotubes with 15(S)-HETE for
4 h on expression of mRNA for (A) C2 proteasome subunit, (B) C5
proteasome subunit, (C) E214k, as determined by quantitative competitive
RT–PCR. Results represent mean7s.e.m. from three separate determina-
tions performed on different occasions with different samples. Differences
are indicated as (a) Po0.05, (b) Po0.01 and (c) Po0.001 from cells
treated with 0 nM 15(S)-HETE.
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Figure 4 Effect of 15(S)-HETE on the expression of mRNA for the C5
proteasome subunit in C2C12 myotubes in the absence (solid boxes) and
presence (open boxes) of 50mM EPA. Results represent mean7s.e.m.
from two separate determinations performed on different occasions with
different samples. Where there was no differences between individual
measurements no standard error is shown. Differences from control are
indicated as (b) Po0.01 and (c) Po0.001 as determined by Student’s
t-test.
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Figure 5 Effect of treatment of C2C12 myotubes with 15(S)-HETE for
2 h on expression of mRNA for (A) C2 proteasome subunit, (B) C5
proteasome subunit. Results represent mean7s.e.m. for three separate
determinations on different samples. Differences from control are indicated
as (a) Po0.05 and (b) Po0.001.
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I and II and the ubiquitin–proteasome proteolytic pathway. Of the
three, the latter is considered to be most important (Lecker et al,
1999), since the former two processes contribute less than 15–20%
of total protein breakdown and do not catabolise myofibrillar
proteins (Lowell et al, 1986). In cancer cachexia, where there is
extensive and specific loss of skeletal muscle, tissue levels of
mRNA for ubiquitin, 20S proteasome a and b subunits and the
ubiquitin-conjugating enzyme, E214k, have been found to be
increased in mouse (Lorite et al, 1998), rat (Temparis et al, 1994)
and humans (Williams et al, 1999). Knowledge of the mechanism
of this increased gene transcription is important for the design of
therapeutic agents, because muscle wastage leads to weakness,
fatigue and eventually death through impairment of respiratory
muscle function (Windsor and Hill, 1998).
Previous studies on protein degradation, induced by PIF in
vitro, suggested 15(S)-HETE as a possible intracellular signal
responsible for the increased transcription of the genes of the
ubiquitin–proteasome proteolytic pathway (Smith et al, 1999).
This suggestion is supported by recent observations (Whitehouse
et al, 2001) showing that EPA, an inhibitor of 15(S)-HETE,
produced in response to PIF, attenuated the development of
muscle catabolism in the MAC16 murine cachexia model by
downregulation of the increased expression of proteasome a-
subunits and chymotrypsin-like enzyme activity. In addition, we
have recently found (Whitehouse and Tisdale, 2001) that both EPA
and a 12/15-lipoxygenase inhibitor, CV-6504, were also effective in
attenuating protein degradation in acute starvation mediated
through the ubiquitin–proteasome pathway. This suggests that in
both models of muscle wasting the same intracellular-mediator is
involved, possibly 15(S)-HETE. The aim of the present study has
been to determine whether 15(S)-HETE alone is capable of
upregulation of the key enzymes of the ubiquitin–proteasome
pathway using C2C12 myotubes.
Using this in vitro system, 15(S)-HETE has been shown to
induce total protein degradation at concentrations between 78 and
312 nM, with a bell-shaped dose–response curve similar to that
previously reported in C2C12 myoblasts (Smith et al, 1999),
although the concentration to produce a maximal effect was
higher in myotubes. Since the effect of PIF on protein catabolism
in myotubes has been shown to be mediated through an
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Figure 6 Effect of treatment of C2C12 myotubes with 15(S)-HETE for
24 h on expression of mRNA for (A) C2 proteasome subunit, (B) C5
proteasome subunit, as determined by quantitative competitive RT–PCR.
Results represent mean7s.e.m., where n¼ 3 representing three separate
determinations on different samples. Differences from control are indicated
as (b) Po0.01 and (c) Po0.001.
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Figure 7 Western blots of soluble extracts of C2C12 myotubes treated
with 0 (lane 1), 156 nm (lane 2), 234 nm (lane 3), 312 nm (lane 4), 480 nm
(lane 5), 630 nm (lane 6), 780 nm (lane 7) and 1560 nM 15(S)-HETE, (lane
8) for 24 h on expression of p42 subunit of 19S regulatory subunit (A),
myosin (B) and actin control (C). Blots were developed with the
respective antibodies as described in Materials and methods, and are
representative of three separate determinations on different samples.
Average densitometric data are presented under the blots.
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upregulation of the ubiquitin–proteasome proteolytic pathway
(Gomes-Marcondes et al, 2002), if 15(S)-HETE was acting as an
intracellular transducer of PIF action then the effect on protein
degradation would also be mediated by this pathway. Accordingly
15(S)-HETE was shown to increase the ‘chymotrypsin-like’ enzyme
activity of the b subunits of the proteasome, suggested to be the
rate-determining step in protein catabolism (Chen and Hochstras-
ser, 1996; Rock et al, 1994), in the same concentration range as that
stimulating total protein degradation. Further confirmation that
15(S)-HETE stimulated expression of the rate-limiting components
of the ubiquitin–proteasome pathway was provided by an
increased mRNA level for proteasome subunits C2 and C5, as well
as E214k, and increased protein levels of proteasome subunit, p42,
over the same concentration range as that inducing total protein
degradation. Previous studies have reported increased proteasome
subunits (Temparis et al, 1994; Lorite et al, 1998) MSS1 (Combaret
et al, 1999) and E214k with increased muscle catabolism in cancer
cachexia, suggesting that they play important roles in protein
degradation. Indeed, cellular levels of the myofibrilar protein,
myosin, were reduced in myotubes treated with 15(S)-HETE over
the same concentration range as that inducing the regulatory
components of the ubiquitin–proteasome proteolytic pathway.
We have suggested (Whitehouse et al, 2001) that EPA attenuates
protein degradation and the increased expression of the key
regulatory components of the ubiquitin–proteasome pathway as a
result of the inhibition of 15(S)-HETE production through the PIF-
induced activation of phospholipase A2 and arachidonate release
(Smith et al, 1999). It was therefore surprising that EPA was able to
attenuate protein degradation and the increase in proteasome
expression induced by 15(S)-HETE. This suggests that EPA also
affects a downstream pathway involved in induction of proteasome
expression by 15(S)-HETE, possibly a nuclear transcription factor,
since Ross et al (1999) have shown that in the pancreatic cancer
cell line, MiaPaCa 2, exposed to EPA for 2 h prior to a pulse of
TNF-a, I-kBa was preserved, suggesting an effect of EPA in
stabilising the NF-kB complex in the cytoplasm.
Watchorn et al (2001) have shown PIF to activate both the
transcription factors NF-kB and STAT3 in hepatic cells. Li et al
(1998) showed that TNF-a stimulated protein loss in C2C12
myotubes involved the ubiquitin–proteasome proteolytic pathway
and was accompanied by nuclear translocation of NF-kB to its
targeted DNA sequence by stimulating phosphorylation, ubiquitin
conjugation and proteolysis of I-kBa. Total protein content and
myosin heavy chain levels in C2C12 myotubes were found to be
unaltered in cells transfected with viral plasmid constructs that
overexpress mutant I-kBa proteins that are insensitive to
degradation by the ubiquitin–proteasome pathway (Li and Reid,
2000). These data suggest that NF-kB is an essential mediator of
TNF-a-induced protein catabolism in differentiated muscle cells.
However, Du et al (2000) found that NF-kB is a repressor of C3
proteasome subunit transcription in muscle cells and that
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Figure 8 (A) Activation of NF-kB binding to DNA as demonstrated by
EMSA. Nuclear extracts of C2C12 myotubes treated with 0 nm (lane 1),
31 nm (lane 2), 156 nm (lane 3), 234 nm (lane 4) or 312 nM 15(S)-HETE
(lane 5) for 30min were compared with cells treated with 0 nm (lane 6),
31 nm (lane 7), 156 nm (lane 8), 234 nm (lane 9) or 156 nM 15(S)-HETE
(lane 10) pretreated with 50mM EPA for 2 h. The gel shown is a
representative example of three separate determinations and the average
densitometric data are presented below the blot. (B) Western blot of I-
kBa levels in cytoplasmic extracts of myotubes treated with 0 nm (lane 1),
3.1 nm (lane 2), 15.6 nm (lane 3), 31 nm (lane 4), 156 nm (lane 5) and
312 nM 15(S)-HETE (lane 6) for 30min or after pretreatment for 2 h with
EPA (50 mM) and treated with 0 nm (lane 7), 3.1 nm (lane 8), 15.6 nm (lane
9), 31 nm (lane 10), 156 nm (lane 11) and 312 nM 15(S)-HETE (lane 12).
Detection was by rabbit polyclonal antisera to residues 1–317 of human I-
kBa. The blot shown is representative of three separate determinations
and the average densitometric data are provided below the blot. (C) The
effect of the NF-kB inhibitor peptide SN50 on 15(S)-HETE induced
upregulation of the ‘chymotrypsin-like’ activity of the proteasome.
Myotubes were treated with the cell-permeable NF-kB inhibitor peptide,
SN50 (18 mM) for 20min prior to the addition of 15(S)-HETE. The activity
shown represents the lactacystin (10 mM) suppressible proteolytic activity.
Differences are indicated as (a) Po0.05 and (b) Po0.01 from those in the
absence of 15(S)-HETE and (c) Po0.01 and (d) Po0.001 from those in the
absence of SN50.
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glucocorticoids stimulate C3 proteasome subunit expression by
opposing this suppressor action. This mechanism is surprising,
since NF-kB normally acts as a transcriptional activator, and the
present study provides some evidence that NF-kB may be involved
in the increase in transcription of the regulatory components of
the ubiquitin–proteasome pathway induced by 15(S)-HETE. Thus,
15(S)-HETE induced elevated levels of NF-kB binding activity in
the nucleus of C2C12 myotubes with a corresponding decrease in
cytosolic I-kBa. The effect was not seen in myotubes pretreated
with EPA, providing a role for EPA in the attenuation of
downstream signalling induced by 15(S)-HETE. The concentra-
tions of 15(S)-HETE affecting the NF-kB/I-kBa system were the
same as those increasing protein degradation and stimulating
increased expression of the key regulatory components of the
ubiquitin–proteasome pathway. Moreover, the NF-kB inhibitor
peptide SN50 (Lin et al, 1995) attenuated the increased proteasome
chymotryptic activity in the presence of 15(S)-HETE. These results
suggests that 15(S)-HETE may induce gene expression through the
transcription factor NF-kB.
The mechanism by which 15(S)-HETE could activate NF-kB is
not known. One possibility is that as 15(S)-HETE is oxidised it
could result in the generation of reactive oxygen species, which
might regulate the redox sensitive NF-kB, possibly through
oxidation of constituent proteins, which could augment DNA-
binding activity or promote the release from, or degradation of I-
kB. Mild oxidative stress has been shown to induce 20S
proteasome subunits and E214k in murine myotubes (Gomes-
Marcondes and Tisdale, 2002). However, it is not clear why 5- and
12-HETE would not have the same properties as 15-HETE if this
were the mechanism. Further studies are required to determine the
role of transcription factors and cellular signalling pathways in the
action of 15(S)-HETE.
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